Abstract
Background
Hepatectomy with tumor thrombectomy is the preferred treatment option for hepatocellular carcinoma (HCC) patients with bile duct tumor thrombus (BDTT); however, the impact of BDTT on their prognosis is unclear.
Objective
We aimed to investigate the long-term surgical outcomes of HCC patients with BDTT.
Methods
The data of HCC patients with and without BDTT who underwent hepatectomy were retrospectively reviewed and the long-term outcomes were compared. For propensity score matching (PSM) analysis, patients were matched in a 1:1 ratio. Subgroup analysis was conducted according to the American Joint Committee on Cancer (AJCC) staging system.
Results
Before PSM, HCC patients with BDTT had more advanced tumor stages and adverse clinicopathological features. Recurrence-free survival (RFS) and overall survival (OS) were significantly higher in the non-BDTT group before PSM (RFS, p < 0.001; OS, p < 0.001), while after PSM, the BDTT group had significantly poorer RFS (p = 0.025). There was no difference in OS between the groups (p = 0.588). Subgroup analysis showed that RFS and OS in AJCC stage I–II patients were significantly poorer in the BDTT group; no differences were found in the AJCC stage III group before or after PSM. When the presence of BDTT was recommended to increase the AJCC staging system by one stage in AJCC stage I–II patients, the predictive ability for RFS and OS was higher.
Conclusions
BDTT was associated with significantly poorer long-term surgical outcomes in AJCC stage I–II patients. A modified AJCC staging system including BDTT status in stage I–II might have a better prognostic ability.
Similar content being viewed by others
Change history
22 January 2022
A Correction to this paper has been published: https://doi.org/10.1245/s10434-022-11335-4
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.
Shah SA, Tan JC, McGilvray ID, et al. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg. 2007;11:464–71.
Zeng H, Xu LB, Wen JM, et al. Hepatocellular carcinoma with bile duct tumor thrombus: a clinicopathological analysis of factors predictive of recurrence and outcome after surgery. Medicine (Baltimore). 2015;94:e364.
Navadgi S, Chang CC, Bartlett A, et al. Systematic review and meta-analysis of outcomes after liver resection in patients with hepatocellular carcinoma (HCC) with and without bile duct thrombus. HPB (Oxford). 2016;18:312–6.
Yeh TS, Wang F, Chen TC, et al. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg. 2014;259:346–54.
Meng KW, Dong M, Zhang WG, et al. Clinical characteristics and surgical prognosis of hepatocellular carcinoma with bile duct invasion. Gastroenterol Res Pract. 2014;2014:604971.
Yu XH, Xu LB, Liu C, et al. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. Dig Dis Sci. 2011;56:252–9.
Wang DD, Wu LQ, Wang ZS. Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study. Hepatobiliary Pancreat Dis Int. 2016;15:626–32.
Kim JM, Kwon CH, Joh JW, et al. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. Medicine (Baltimore). 2015;94:e450.
Rammohan A, Sathyanesan J, Rajendran K, et al. Bile duct thrombi in hepatocellular carcinoma: is aggressive surgery worthwhile? HPB (Oxford). 2015;17:508–13.
Ikenaga N, Chijiiwa K, Otani K, et al. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009;13:492–7.
Yeh CN, Jan YY, Lee WC, et al. Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg. 2004;28:471–5.
Noda T, Nagano H, Tomimaru Y, et al. Prognosis of hepatocellular carcinoma with biliary tumor thrombi after liver surgery. Surgery. 2011;149:371–7.
Wong TC, Cheung TT, Chok KS, et al. Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus. HPB (Oxford). 2015;17:401–8.
Shiomi M, Kamiya J, Nagino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery. 2001;129:692–8.
Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery. 2000;128:779–83.
Orimo T, Kamiyama T, Yokoo H, et al. Hepatectomy for hepatocellular carcinoma with bile duct tumor thrombus, including cases with obstructive jaundice. Ann Surg Oncol. 2016;23:2627–34.
Liu PH, Hsu CY, Hsia CY, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol. 2016;64:601–8.
Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37:481–91.
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845–7.
Kim DS, Kim BW, Hatano E, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korea–Japan multicenter study. Ann Surg. 2020;271:913–21.
Clark W, Schulz MD. Hepatoma, with invasion of cystic duct and metastasis to third lumbar vertebra. N Engl J Med. 1947;237:673–6.
Jang YR, Lee KW, Kim H, et al. Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg. 2015;19:167–72.
Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909–22.
Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002;24:395–403.
Lu WP, Tang HW, Yang ZY, et al. A proposed modification for the Barcelona Clinic Liver Cancer staging system: adding bile duct tumor thrombus status in patients with hepatocellular carcinoma. Am J Surg. 2020;220:965–71.
Acknowledgment
The authors wish to thank all the staff of the participating hospitals for their kind cooperation and support, as well as all patients for their participation.
Funding
This study was funded by the Startup Fund for scientific research, Fujian Medical University (2018QH1112) and the Natural Science Foundation of Fujian Province (2020J011105).
Author information
Authors and Affiliations
Contributions
J-YW, J-XS, J-YW, X-XH, YB, Y-GW, Z-BZ, J-YZ, S-QC, and M-LY contributed to the surgery and the collection of data. J-YW, J-XS, and J-YW contributed to the analysis of data. S-QC and M-LY served as scientific advisors. J-YW, J-XS, S-QC, and M-LY interpreted the results, and wrote the article, and Y-GW, Z-BZ, J-YZ, S-QC, and M-LY made critical comments and revised the article. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Disclosure
Jun-Yi Wu, Ju-Xian Sun, Jia-Yi Wu, Xiao-Xiao Huang, Yan-nan Bai, Yong-Gang Wei, Zhi-Bo Zhang, Jian-Yin Zhou, Shu-Qun Cheng, and Mao-Lin Yan report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: Fig. 2 c and d was corrected.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wu, JY., Sun, JX., Wu, JY. et al. Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. Ann Surg Oncol 29, 949–958 (2022). https://doi.org/10.1245/s10434-021-10799-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10799-0